Optimizing Outcomes in Myeloma

Amy Pierre, MSN, ANP-BC, Flatiron Health and Memorial Sloan Kettering, New York, NY and Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC

Recorded on March 10, 2026

Amy Pierre, MSN, ANP-BC
Senior Clinical Director, Research Oncology, Flatiron Health
Nurse Practitioner, Memorial Sloan Kettering Cancer Center
New York, NY
Peter Voorhees, MD
Director, Outreach for Hematologic Malignancies, Plasma Cells Disorder
Program, Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Charlotte, NC
Professor, Cancer Medicine
Wake Forest University School of Medicine
Winston-Salem, NC
In this episode, Dr. Peter Voorhees from the Levine Cancer Institute and Amy Pierre, MSN, RN, ANP BC from Flatiron Health and Memorial Sloan Kettering, break down the evolving landscape of myeloma, from early signs and diagnostic criteria to frontline therapy, transplant decisions, and T- cell redirecting therapies. They explore real world challenges in survivorship, treatment toxicity, and disparities in access to advanced therapies, offering practical insights to help care teams support patients more effectively. Tune in for an informative and forward looking discussion shaping the future of myeloma management.

Blood Cancer United Resources:

• Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
• Blood Cancer United Resources for Patients